Deltagen Inc Watch

from 10-K 62 pages Confidential Portions of This Document Have Been Omitted Pursuant to a Request for Confidential Treatment and Have Been Filed Separately With the Commission. Agreement and Plan of Merger and Reorganization Dated as of January 15, 2002 Among Deltagen, Inc., Xp Acquisition Corporation and Xenopharm, Inc

from 8-K 21 pages Registration Rights Agreement Dated as of February 16, 2002 (This “Registration Rights Agreement”), Between Bristol-Myers Squibb Company, a Delaware Corporation (“Seller”), and Deltagen, Inc., a Delaware Corporation (“Buyer”)

from 8-K 3 pages Amendment (The “Amendment”), Dated as of February 14, 2002, to the Purchase Agreement Dated as of February 8, 2002 (The “Purchase Agreement”), Between Bristol-Myers Squibb Company, a Delaware Corporation (“Seller”), and Deltagen, Inc., a Delaware Corporation (“Buyer”). Whereas Buyer and Seller Desire to Amend the Purchase Agreement as More Fully Set Forth Below. Now, Therefore, in Consideration of the Mutual Covenants and Agreements Contained Herein and for Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, Buyer and Seller Hereby Agree as Follows: Section 1. Definitions; References. Unless Otherwise Specifically Defined Herein, Each Term Used Herein Shall Have the Meaning Assigned to Such Term in the Purchase Agreement. Section 2. Closing. (A) the First Sentence of Section 2.01(a) of the Purchase Agreement Is Hereby Deleted in Its Entirety and Amended and Restated as Follows

from 8-K 97 pages Purchase Agreement Between Bristol-Myers Squibb Company and Deltagen, Inc. Dated as of February 8, 2002 Sale of Bmsprl, L.L.C